

Central Lancashire Online Knowledge (CLoK)

| | |
|----------|---|
| Title | Poor Oral Health and its Neurological Consequences: Mechanisms of Porphyromonas gingivalis Involvement in Cognitive Dysfunction |
| Type | Article |
| URL | https://clock.uclan.ac.uk/27830/ |
| DOI | https://doi.org/10.1007/s40496-019-0212-8 |
| Date | 2019 |
| Citation | Olsen, Ingar and Singhrao, Simarjit Kaur (2019) Poor Oral Health and its Neurological Consequences: Mechanisms of Porphyromonas gingivalis Involvement in Cognitive Dysfunction. Current Oral Health Reports. |
| Creators | Olsen, Ingar and Singhrao, Simarjit Kaur |

It is advisable to refer to the publisher's version if you intend to cite from the work.
<https://doi.org/10.1007/s40496-019-0212-8>

For information about Research at UCLan please go to <http://www.uclan.ac.uk/research/>

All outputs in CLoK are protected by Intellectual Property Rights law, including Copyright law. Copyright, IPR and Moral Rights for the works on this site are retained by the individual authors and/or other copyright owners. Terms and conditions for use of this material are defined in the <http://clock.uclan.ac.uk/policies/>

1 Version 2019-01-26

2 Curr Oral Health Rep.

3 **Poor Oral Health and its Neurological Consequences:**
4 **Mechanisms of *Porphyromonas gingivalis* Involvement in**
5 **Cognitive Dysfunction**

6

7 **Ingar Olsen^{1*} • Sim K. Singhrao²**

8 ¹Department of Oral Biology, Faculty of Dentistry, University of Oslo, Oslo, Norway

9 ²Dementia and Neurodegenerative Diseases Research Group, Faculty of Clinical and
10 Biomedical Sciences, School of Dentistry, University of Central Lancashire, Preston, UK

11

12 **Corresponding author:** [Prof. Ingar Olsen](#)

13 **E-mail:** ingar.olsen@odont.uio.no

14 **Telephone:**

15 **ORCID ID (IO) and**

16 **(SKS):** orcid.org/0000-0001-9573-5963

17

18

19 **Abstract**

20 **Purpose of review:** There is an increasing body of evidence from epidemiology and
21 laboratory investigations on periodontal disease being a risk factor for dementia. In particular,
22 *Porphyromonas gingivalis* infections in animal models suggest causal associations with
23 Alzheimer's disease (AD). This review focusses on how *P. gingivalis* infections promote the
24 incidence of functional loss in AD.

25 **Latest findings:** The risk of the sporadic form of AD doubles when periodontitis persists for
26 ten or more years. AD differs from other forms of dementia in that the clinical signs together
27 with the presence of amyloid-beta (A β) plaques and neurofibrillary tangles must be present at
28 autopsy. *P. gingivalis* oral infections in mice have demonstrated all of the characteristic
29 pathological and clinical features of AD following infection upon their entry to the brain.

30 **Summary:** Multiple factors (inflammation, A β oligomers, and bacterial factors) are likely to
31 disrupt neuronal communication channels (synapses) as a plausible explanation for the
32 functional loss.

33 Abstract: 150 words

34 Bulk of article: 3,640 words

35

36

37 **Keywords** Alzheimer's disease; Periodontitis; Interaction; *P. gingivalis*; Virulence factors

38

39 ~~*Corresponding author: Ingar Olsen, Department of Oral Biology, Faculty of Dentistry,
40 University of Oslo, P.O.B. 1052 Blindern, 0316 Oslo, Norway. E-mail address:
41 ingar.olsen@odont.uio.no~~

42 Introduction

43 Longstanding periodontitis, formerly known as “chronic” periodontitis has an adverse effect
 44 on a number of complex human diseases associated with longstanding inflammation [1-3].
 45 Recent research has linked poor oral hygiene to ~~other~~ neurological conditions that manifest
 46 with dementia. Currently they include the sporadic form of Alzheimer’s disease (AD), and the
 47 Lewy body Parkinson’s disease (dementia) [4-6]. Amyloid-beta (A β) plaques are central to all
 48 forms of dementia, but are more important to AD pathology. A significant body of literature
 49 considers the A β plaques of AD and the α -synuclein of Lewy bodies to be antimicrobial
 50 peptides that combat infections of the brain [7-10]. This concept may provide vital clues to
 51 the occurrence of these neuropathological lesions.

52 *Porphyromonas gingivalis*

53 *Porphyromonas gingivalis* is found in the oral cavity (saliva) of all humans where it may or
 54 may not cause oral pathology, but is able to tolerate low concentrations of oxygen
 55 (microaerophilic). In addition, recent research has implicated *P. gingivalis* as the keystone
 56 pathogen of periodontitis, which is an inflammatory disease constituting complex dysbiotic
 57 microbial community residing below the gumline, within “pockets”. *P. gingivalis* appears to
 58 translocate from the saliva to the subgingival location using neutrophils as “Trojan horses” in
 59 some individuals because clinical observations suggest that not everyone progresses to
 60 manifesting periodontal disease.

61
 62 The mouth harbours a microbiome, which essentially is a reservoir of health
 63 promoting microbes until their balance changes to more pathogenic forms. The fact that *P.*
 64 *gingivalis* can act as a commensal, and provides us with an opportunity to discuss the role of
 65 its source of *Porphyromonas gingivalis*—its primary oral source to its access of the brain in
 66 relation to cognitive dysfunction. This is not only because AD is a prime example of a
 67 dementing neurological disease but also for that has a plausible—the established— association
 68 with of *P. gingivalis*—with both the AD brain [11, 12], and periodontitis as a keystone
 69 bacterium [12]. In addition, This is strengthened by the development of models for
 70 periodontal infection and AD in mice *P. gingivalis* infection to the brain directly from its
 71 primary oral niche—[13] where it has been demonstrated to ~~can~~ reproduce the cardinal
 72 hallmark pathology inclusive of A β plaques, phosphotau [14], and cognitive function—in
 73 experimental mice—[15-17].

74

75 Alzheimer's disease

76 AD is end of life stage and the most common example of dementia. The cardinal clinical signs
77 are cognitive decline with deterioration in memory. The hippocampus is the region of the
78 brain where memory is processed and the functional loss has been associated with the death of
79 neurons in specific regions of the brain related to memory. AD has a long preclinical phase
80 (20 years) with the duration of suffering lasting on average for 8-10 years and longer [18]. At
81 the preclinical stage of the illness, the individual may not seek medical help. Usually a family
82 member or the caregiver of the person with declining cognition and memory may voice their
83 concern to a health care professional. This may be their general medical practitioner (GP) or a
84 health care professional (district nurse). The first stage in exploring this health complaint is
85 for the caregiver to take the person (with suspected dementia signs) to his/her GP. The GP
86 will then refer the person on to a memory service to establish a more formal clinical
87 diagnosis, and initiate treatment and support. The final diagnosis of AD rests with both the
88 clinical history together with the demonstration of the neuropathological occurrence of A β
89 plaques and hyperphosphorylated tau protein binding to neurofibrillary tangles in a
90 characteristic pattern and distribution in the specific regions of the brain. AD neuropathology
91 can co-exist with other neurological and/or vascular pathologies because it is not an isolated
92 disease.

93

94 Plausible cause of Alzheimer's disease and Lewy-body dementia

95 The cause of the sporadic forms of the neurological diseases under discussion (AD and
96 Parkinson's disease with Lewy bodies) remains unclear. However, amongst others, the risk
97 factors include ageing and inheritance of the apolipoprotein E gene allele 4 (*APOE ϵ 4*) [19,
98 20]. The *APOE ϵ 4* susceptibility gene links with environmental risk factors that include the
99 host's dysbiotic oral microbiome [21]. *P. gingivalis* infections of the brain in laboratory mice
100 induced with periodontitis demonstrate excessive oxidative stress and inflammation [13-15,
101 22].

102 Lewy bodies are intra-neuronal cytoplasmic inclusions composed of synuclein and
103 other proteins lying within the pigmented neurons of the substantia nigra, limbic and the
104 cerebral cortex regions of the brain. The clinical symptoms of Parkinson's disease in its purest
105 form are tremor, immobility and rigidity of muscles. However, cognitive deficit occurs when
106 Parkinson's disease co-exists with dementia (Lewy body Parkinsonian dementia), see
107 comment above related to mixed pathologies. Epidemiological investigations [4, 5] in a

108 Taiwanese population have linked this to periodontal disease. As mentioned earlier, the A β
109 protein of AD plaques and the α -synuclein within Lewy bodies are a form of broad-spectrum
110 antimicrobial peptides, released following infection, including that caused by the periodontal
111 pathogen *P. gingivalis* [7-10, 14]. If A β and α -synuclein represent the host's response to a
112 previous infection, it follows that these neurodegenerative diseases have causative
113 associations with microbes during their development. This has given rise to the antimicrobial
114 protection hypothesis [23] linking infection as a plausible trigger for the sporadic form of AD.
115 If this theory becomes widely accepted, then explaining the existing oxidative stress, the
116 activated complement, the longstanding inflammation and the defects in the blood-brain
117 barrier (BBB) would be easy in the context of *P. gingivalis* infection [13, 22, 24]. All of the
118 above-mentioned signaling cascades and others (not included here), would enhance the role of
119 A β as an antimicrobial peptide in killing the elusive invader(s) and/or the little understood
120 brain's own microbiome converting to a pathobiome. In addition, the elderly are unlikely to
121 be immuno-privileged because the BBB defects in the 70+ year's age group are associated
122 with more rapid cognitive decline [25] and could have implications for pathogen entry.

123

124 **Plausible cause of cognitive deficit**

125 What actually causes the cognitive deficit during dementia onset is unclear, because the
126 individual examples of dementia such as AD are seldom pure. However, the amyloid cascade
127 hypothesis originally focused on A β deposits as a possible cause [26]. Subsequent
128 immunological therapy to remove A β plaques from the brains of AD patients disproved the
129 notion that insoluble A β deposits contribute to cognitive dysfunction [27]. Prior to the
130 amyloid hypothesis, the synaptic loss hypothesis of Terry et al. [28] and Masliah et al. [29]
131 originated from the fact that specific neuronal loss may be due to synaptic loss. The revised
132 version of the amyloid cascade hypothesis has incorporated soluble oligomeric A β in the
133 synaptotoxicity and cognitive impairment theory [30]. It is possible that there is close
134 interplay between the mechanisms underlying these three hypotheses. After all, it is highly
135 plausible that microbial debris, inflammatory mediators, oligomeric A β , smaller tau peptides
136 released by gingipains, and pathogen activated inflammasomes [31], can all act to disrupt
137 synapses and result in cognitive deficit.

138

139 **Relationship between periodontitis and AD**

140 The idea of dementia being a risk factor for periodontitis is undisputable, but then one would
141 expect all demented individuals to have periodontitis by the time of death. Literature suggests
142 the formerly known “chronic” periodontitis has a clearer relationship with a subgroup of AD
143 cases [32-36]. Significant progress will only be made to find the actual direction of this
144 relationship, once we better understand the parameters that should be included and/or
145 excluded from the investigation in case control and/or cohort studies. For example, we now
146 understand that periodontitis only becomes a risk factor for AD development some 10 years
147 after it is diagnosed [37, 38]. This would imply that studies conducted in less than 10-year
148 cohort analysis would provide inconclusive results [39]. One suggested risk of developing AD
149 is having fewer remaining teeth (loss of up to 9 teeth) in early to mid-life due to periodontitis
150 [30, 40], resulting from longstanding poor oral hygiene. For a more comprehensive discussion
151 on the direction of the relationship between oral health and risk of developing AD, see Daly et
152 al. [41]. There is agreement that periodontitis doubles the risk for developing late onset AD
153 with an odds ratio of 2.2 (95% CI 1.1, 4.5) 10 years after its initial diagnosis [37, 38]. An
154 interventional study on the periodontal treatment in AD patients [42] indicated a plausible
155 causal relationship in demented individuals. It is suggested that patients with early stage
156 dementia (at the ~~time of point when they~~ visiting the memory clinic for initial diagnosis) show
157 worsening oral hygiene [43], implying that dementia may be the risk factor for periodontal
158 disease in this group of patients. It is also suggested that if dental intervention is provided at
159 the early stage of dementia onset, it would delay the speed of cognitive deterioration. Early
160 intervention is important and memory clinics should consider taking it on at the time the
161 initial diagnosis [43]. However, to confirm the direction of the relationship, more studies with
162 larger cohorts are needed in the “at risk” subpopulation of individuals whose periodontitis co-
163 exists with AD cases. In addition, future interventional studies should include participants
164 who suffer from periodontitis approaching the risk age for dementia (pre 65-year age) for
165 maximal impact on delaying the onset of AD.

166

167 **Relationship of *P. gingivalis* with AD development**

168 As mentioned, *P. gingivalis* is considered a keystone pathogen in periodontitis [12] and it is
169 adept at manipulating the sub-gingival microbiome and the host’s immune system [44-49]. *P.*
170 *gingivalis* is an intracellular pathogen that has been used to develop AD via periodontal
171 infection in mice [13, 14]. The infection periodontal model of Ilievski et al. [14] produced the
172 AD defining hallmark lesions in the mouse brains ($A\beta$ and phosphotau neurofibrillary

173 tangles), a finding reproduced in mice by Dominy et al. [50]. Since the Ilievski and the
174 Dominy models were of wild type mice, there is a high probability that A β was cleaved from
175 its precursor protein into various oligomer sizes following oxidative stress initiated by *P.*
176 *gingivalis*, which in turn activated cathepsin B within the endo/lysosomes [22, 51]. This
177 intracellular processing of A β agrees with the earlier report of Wu et al. [15] showing, that
178 metabolic processing of the amyloid precursor protein after *P. gingivalis* lipopolysaccharide
179 (LPS) was administered into cathepsin B sufficient mice. Other studies in which either *P.*
180 *gingivalis* or its LPS was introduced, supported the development of the AD-like clinical
181 phenotype [15-17, 52] resulting in impaired spatial learning and memory. All of these
182 investigations support a causal relationship of periodontitis with the development of AD.

183

184 **Mechanisms of cognitive deficit by *P. gingivalis* infection**

185 *Soluble oligomeric A β and BBB defects*

186 In line with Dominy et al. [50] confirming *P. gingivalis* genetic footprints (DNA) in the AD
187 brains, *in vivo* infection models of periodontitis are recapitulating hallmark proteins and the
188 emerging phenotype is supporting cognitive deficit [14-17, 52]. *P. gingivalis* produces two
189 types of cysteine proteases (gingipains). They are the lysine specific Kgp and the arginine
190 specific RgpA and RgpB gingipains [53]. A novel finding described by Dominy et al. [50] is
191 the capacity of these proteases to hydrolyse the biochemical structure of the protein tau, and
192 this opens up future avenues for research.

193 Gingipains activity has the potential to erode endothelial tight junction proteins [24] as
194 supported by the *P. gingivalis*/host interactome study [54]. Cognitive deterioration due to
195 BBB defects in the human elderly individuals are also documented [25] and this may yet be
196 another contributory factor in mice models displaying AD-like clinical phenotype. In addition,
197 if the soluble form of the oligomeric A β can interfere with synapses and contribute to
198 cognitive deficit, as proposed by Cline et al. [30]. Then *P. gingivalis* oral infection can also
199 contribute to this protein following its entry into the brain [14, 50].

200

201 *Inflammation and inflammatory mediators in general*

202 Numerous studies have shown that LPS from Gram negative bacteria either administered
203 directly into the peritoneum or the brain, induce neuroinflammation in the form of glial cell
204 activation [55] and when measured, the inflammatory response is accompanied by learning
205 and memory impairment [56, 57] as a result of IL-1 β secretion following peripheral challenge
206 with LPS [58]. This is in agreement with the Wu et al. [15] hypothesis that systemic

207 administration of *P. gingivalis* LPS leads to cognitive deficit following A β liberation in an IL-
208 1 β receptor dependent pathway on neurons, (also see [21]). IL-1 β cytokine is implicated in
209 synaptic loss [59, 60] and with reduced long-term potentiation, which is a unit of memory
210 [59], supporting the role of this cytokine in deteriorating cognition.

211

212 *P. gingivalis*, complement, and immune dysbiosis

213 Gingipains are virulence factors of great importance to the immune subversion activity of *P.*
214 *gingivalis* [53]. In the context of the complement cascade, these proteases play a major role.
215 *P. gingivalis* oral infection of apolipoprotein E^{-/-} mice demonstrated complement activation in
216 their brains [13]. Activation of complement does take place in AD brains, where A β plaques
217 are the suggested trigger [61]. If, according to the novel hypothesis of Allen [62] that A β
218 senile plaques are miniature foci of bacterial biofilms, and that the antimicrobial protection
219 theory of Moir et al. [23] supporting the A β antimicrobial peptide idea then the downstream
220 immune activity triggering complement activation in AD brains does fit. Inappropriately
221 activated complement compromises the function of healthy neurons, because of their
222 inadequate shielding from protective proteins that rescue them from the non-specific mode of
223 activity of this powerful innate immune signaling cascade [63]. During complement
224 activation, release of several small proteins (opsonins) takes place, which then opsonize to
225 neurons [13]. Depending on the site of opsonin binding to the neuron, (e.g. at the synaptic
226 cleft), there remains a potential to disrupt the path of neuronal communication and give way
227 to cognitive dysfunction. In addition, the continuation of this cyclic cascade will generate
228 more cytokines and contribute to cognitive deficit (see above).

229 *P. gingivalis* infection continues to cleave complement components (C1-C5) through
230 its gingipains activity, and prevents both deposition of C3b on the bacterial surface and
231 capture of the C4b binding protein [64-68]. By hijacking the complement regulator C4bp on
232 the bacterial surface, *P. gingivalis* prevents assembly of the membrane attack complex and
233 acquires the ability to regulate C3 convertase [66]. Accordingly, the gingipains do not only
234 destroy complement through proteolytic degradation, but they also inhibit activation of
235 complement by binding to the complement inhibitor C4bp [66]. This inhibits complement
236 action and results in a local accumulation of the anaphylatoxin C5a [69]. *P. gingivalis* also
237 exerts C5 convertase-like enzymatic activity and exploits complement-Toll like receptor
238 (TLR) crosstalk to subvert host defenses and thus escape elimination from the host [45].
239 Zhang et al. [52] recently demonstrated that the mechanism by which *P. gingivalis* impaired

240 spatial learning and memory is via TLR crosstalk because inhibiting this pathway rescued
241 memory in their infection mouse model.

242 As an analogy to TLR signaling, our in house data clearly showed that CD14, an LPS
243 binding receptor, expressed on healthy IMR32 neurons (also participates in TLR signaling)
244 was completely or partially removed following exposure to endo/exotoxins from *P. gingivalis*
245 ATCC 33277^T and W50, respectively (see Figure 1). Such mechanisms lead to defective
246 immune surveillance because of their influence in remodeling the periodontal microbiota into
247 a dysbiotic state. *P. gingivalis* can also reduce the antibacterial and proinflammatory activity
248 of C5a by deiminating its C-terminal arginine residues [70]. Degradation of complement
249 proteins probably allows colonization and proliferation of bacteria possessing higher
250 sensitivity towards complement killing than found in *P. gingivalis* itself [47]. Thus, *P.*
251 *gingivalis* may support survival of the entire biofilm community by helping bystander bacteria
252 evade complement mediated killing [46], whilst neurons survive with compromised function.
253 These activities have consequences for the developing neuropathology. Thus, the
254 neuropathology and the clinical functional loss together, constitute the AD diagnosis. *P.*
255 *gingivalis* infection under laboratory conditions are supporting both of these possibilities [13-
256 17, 22, 24, 52].

257

258 *Bacterial factors disrupting synapses*

259 Our in-house *in vitro* studies in which IMR32 (neuroblastoma-derived) neurons challenged
260 with *P. gingivalis* virulence factors (containing LPS and gingipains) indicated considerable
261 alterations in their actin cytoskeletal filaments following their detection with fluorescein-
262 phalloidin dye. The LPS binding to cell surface membranes caused blebbing [11], whilst the
263 protease caused the cells to withdraw their processes and round up (see Figure 2). In
264 summary, the structural alteration of the IMR32 neurons, *in vitro*, could provide the basis for
265 the failure of communication between neighboring cells. ~~In addition, excess
266 bacterial/inflammatory mediators possibly trap between micro spaces of opposing (pre-post)
267 synapses (synaptic clefts) or adversely affect synaptosomes during their neurotransmitter
268 release contributing to cognitive loss. These areas are open to future investigations in relation
269 to memory.~~ Infection of microglia with *P. gingivalis* in mice has promoted cell migration and
270 an inflammatory response through gingipain-mediated activation of protease-activated
271 receptor-2 [71]. We need to clarify if and how infectious episodes impair memory at the
272 synaptosomal level, rather than at the synaptic cleft level. Such information may refine our

273 understanding at an earlier stage of deteriorating cognition albeit at the neurotransmitter
274 release and its uptake levels.

275

276 **Dysbiosis of immune defense by alternative means**

277 miRNA has a role in the virulence of *P. gingivalis*, contributing to modulation of host-cell
278 immune responses in a manner that promotes bacterial survival, and progressively reduces the
279 host's protective function [49]. Some miRNAs are even associated with *P. gingivalis* itself
280 [72], while others (miRNA-128, miRNA-146, miRNA-203, and miRNA-584) are host
281 derived for inflammation. Bacterium-associated miRNAs are likely to influence the innate
282 immune response against *P. gingivalis*, whereas LPS from this bacterium may affect the level
283 of the host's miRNA-mRNA interactions. **These miRNA-dependent effects may supplement
284 other forms of deception exerted by *P. gingivalis* thus subverting innate and adaptive immune
285 responses possibly by altering gene function [54, 69].**

286

287 ***P. gingivalis* and tau protein phosphorylation**

288

289 As mentioned earlier, Ilievski et al. [14] demonstrated that *P. gingivalis* infection can lead to
290 tau phosphorylation and neurofibrillary tangle formation in mice. The neurons that develop
291 these hallmark lesions in the human AD brain are cells with compromised function, and the
292 structural change in the nerve cell soma and axons, the later disrupting their connectivity. The
293 effect of gingipains on the integrity of actin filaments seen with IMR32 neurons (Figure 2)
294 may be analogous to the neurofibrillary tangle bearing neurons in AD. This structural change
295 is likely to be detrimental to their communications with other brain cells resulting in
296 deteriorated cognition.

297 Previously, we have discussed outer membrane vesicles (microbullets) from *P.*
298 *gingivalis* [73] playing a role in AD development. *P. gingivalis* cultures produce them in vast
299 numbers, suggesting they constitute the main superhighway of communication with other
300 bacteria in the biofilm [74]. Since they carry additional arsenals of weapons to manipulate
301 their entry into disparate organs, disrupt actin structures, erode epithelial junctional proteins,
302 hijack phagocytosis, destroy tissues, and affect complement related genes, they may also be
303 responsible for transducing proinflammatory signaling cascades that ultimately lead to disease
304 defining lesion development and cognitive decline, typical of clinical AD.

305 Ilievski et al. [14] demonstrated a chronic infection with live *P. gingivalis* strain W83
306 for 22 weeks with both the hallmark lesions (A β and NFTs) that characterize AD with tau

Commented [SKS<od1]: I think this is the sentence asked to be clarified?, needs addressing

307 protein phosphorylation at the serine396 (ser396) residue. This generated a new concept that an
308 oral infective focus in neurological diseases may result in dementia. Up until now, abnormally
309 phosphorylated tau protein has not featured negatively in the pathophysiology of periodontal
310 disease *per se*. However, Adamowicz et al. [75] implicated the role of glycogen synthase kinase
311 3 (GSK-3) in bacterial-induced periodontitis because its inhibition rescued bone loss. Thus,
312 GSK-3 may be influencing phosphorylation of brain tau via immune responses mediated by *P.*
313 *gingivalis*, in the Ilievski et al. [14] study. GSK-3 β appears to mediate proinflammatory
314 cytokine production during bacterial infections because inhibition of GSK-3 β leads to an innate
315 hypo-reactivity to oral pathogens [76]. Macrophages treated with LPS, *in vitro* suggest that
316 GSK-3 β stimulates interferon- β (IFN- β) production via c-Jun thus activating a transcription
317 factor (ATF)-2-dependent mechanism [76]. GSK-3 β also negatively regulates production of the
318 endogenous IL-1 β antagonist, IL-1R, via its ability to regulate the MAPK and ERK 1/2 in LPS-
319 stimulated innate immune cells. There is no doubt that further research will widen investigation
320 of these pathways for more direct causal links with oral disease and dementing diseases with
321 cognitive deterioration.

322 The Dominy et al. [50] publication has provided a stronger argument for the role of
323 pathogenic tau in AD development. In their *in vitro* neuronal culture system, Dominy et al.
324 [50] demonstrate that tau is a substrate for gingipains and show a low molecular weight band
325 corresponding to a novel tau peptide. Further research will establish if it is neurotoxic or not.

326

327 ***P. gingivalis* and lymphocytes**

328 It is possible that T cell entry into the AD brain is restricted and this somehow influences
329 ineffective clearance of the A β by macrophages and the resident microglia. Baek et al. [77]
330 found that Treg cells (subpopulation of T cells) had an effect on cognitive function by
331 decreasing A β deposition and inflammatory cytokine secretion in a 3xTg-AD mice model. In
332 contrast, depletion of Tregs increased the onset of cognitive deficit, accelerated the amount of
333 the A β burden, enhanced microglia/macrophage responses and decreased glucose metabolism
334 in 3xTg-AD mice. In patients with atherosclerosis, the Treg population was reduced if they
335 harbored type II fimA of *P. gingivalis* compared to those with other types of fimbriae [78].
336 Therefore, *P. gingivalis* type II fimA could be associated with dysregulation of Tregs in
337 extraoral lesions. Severe immunosuppression seems to favor not only colonization with
338 varying serotypes of periodontopathogenic bacteria, but also with species not commonly
339 found in the subgingival microbiota [79]. In the brain, this may contribute to the

340 establishment of a multi species microbiota, previously reported in AD patients [80]. In
341 addition, accumulation of insoluble and toxic A β 42 has detrimental effect on the neighboring
342 neurons and their connections, which may have further implications for neurodegeneration
343 and related cognitive loss.

344

345 **Conclusions**

346 Dominy et al. [50] have recently provided robust data linking the main pathogen (*P.*
347 *gingivalis*) of periodontitis with the cause of AD. This bacterium appears to migrate from the
348 mouth to the brain of some individuals as they age and a significant proportion of subjects
349 who go onto developing AD. This further highlights the possibility that AD has a microbial
350 infection origin. Ilievski et al. [14] provide evidence for *P. gingivalis* infection having causal
351 associations by reproducing the hallmark lesions. Four independent studies carried out in mice
352 infected with *P. gingivalis* provide causal links through impaired learning and memory. The
353 suggested mechanism is related to the TLR crosstalk and this may have relevance to the
354 inflammasome formation with the resulting cytokines (mature IL-1 β) being linked to memory
355 disturbances.

356 These studies reinforce the advice that oral hygiene is important in keeping pathogens
357 low and encouraging greater diversity of commensals (health promoting bacteria). This
358 provides a healthy microbiome and better general health. Health authorities need to heed this
359 warning and take research based evidence seriously. The UK NHS England provides a
360 recommendable oral health toolkit for the elderly to maintain better oral hygiene with the aim
361 of delaying/preventing AD.

362

363 **Conflict of Interest** The authors declare no conflict of interest.

364

365 **Human and Animal Rights and Informed Consent**

366 Not applicable. This is a review of literature and does not rely on freshly obtained data from
367 human and/or animal studies. Figures are from our in-house cell culture studies that are
368 exempt from ethical issues.

369

370 **References**

371

372 Papers of particular interest, published recently, have been highlighted as:

373 *Of importance

374 **Of major importance.

375 ***Of significant importance

376

- 377 1. Olsen I. From the Acta Prize Lecture 2014: the periodontal-systemic connection seen
378 from a microbiological standpoint. *Acta Odontol Scand.* 2015; 73(8): 563-8. DOI:
379 10.3109/00016357.2015.1007480.
- 380 2. Olsen I, Singhrao SK. Can oral infection be a risk factor for Alzheimer's disease? *J*
381 *Oral Microbiol.* 2015; 7: 29143. DOI: 10.3402/jom.v7.29143.
- 382 3. Olsen I, Singhrao SK, Potempa J. Citrullination as a plausible link to periodontitis,
383 rheumatoid arthritis, atherosclerosis and Alzheimer's disease. *J. Oral Microbiol.*
384 2018; 10(1):1487742. DOI: 10.1080/20002297.2018.1487742.
- 385 4. **Chen CK, Wu YT, Chang YC. Periodontal inflammatory disease is associated with
386 the risk of Parkinson's disease: a population-based retrospective matched-cohort
387 study. *PeerJ.* 2017; 5:e3647. DOI: 10.7717/peerj.3647. **Reducing periodontitis may**
388 **modify the risk of developing Parkinson's disease.**
- 389 5. **Chen CK, Huang JY, Wu YT, Chang YC. Dental scaling decreases the risk of
390 Parkinson's disease: A nationwide population-based nested case-control study. *Int J*
391 *Environ Res Public Health.* 2018; 15(8). pii: E1587. DOI: 10.3390/ijerph15081587.
392 **First study to show that patients without periodontitis who received dental**
393 **scaling over 5 consecutive years had a significantly lower risk of developing**
394 **Parkinson's disease.**
- 395 6. **Pang S, Li J, Zhang Y, Chen J. Meta-analysis of the relationship between the
396 *APOE* gene and the onset of Parkinson's disease dementia. *Parkinsons Dis.* 2018;
397 2018: 9497147. DOI: 10.1155/2018/9497147. **APOE genotypes, ε3/4 and ε4/4 may**
398 **be risk factors for Parkinson's disease dementia.**
- 399 7. **Soscia SJ, Kirby JE, Washicosky KJ, Tucker SM, Ingelsson M, Hyman B, et al.
400 The Alzheimer's disease-associated amyloid beta-protein is an antimicrobial peptide.
401 *PLoS One.* 2010; 5(3): e9505. DOI: 10.1371/journal.pone.0009505. **Abeta is a**
402 **hitherto unrecognized antimicrobial peptide that may normally act in the innate**
403 **immune system.**
- 404 8. Kumar DK, Choi SH, Washicosky KJ, Eimer WA, Tucker S, Ghofrani J, et al.
405 Amyloid-β peptide protects against microbial infection in mouse and worm models of

Formatted: Hidden

Formatted: Hidden

- 406 Alzheimer's disease. *Sci Transl Med.* 2016; 8(340): 340ra72. DOI:
407 10.1126/scitranslmed.aaf1059.
- 408 9. **Park SC, Moon JC, Shin SY, Son H, Jung YJ, Kim NH, et al. Functional
409 characterization of alpha-synuclein protein with antimicrobial activity. *Biochem*
410 *Biophys Res Commun.* 2016; 478(2): 924-8. DOI: 10.1016/j.bbrc.2016.08.052.
411 **Alpha-synuclein appears to be a natural antimicrobial peptide in addition to**
412 **having a role in neurotransmitter release.**
- 413 10. Eimer WA, Vijaya Kumar DK, Navalpur Shanmugam NK, Rodriguez AS, Mitchell
414 T, Washicosky KJ, et al. Alzheimer's disease-associated β -Amyloid is rapidly seeded
415 by Herpesviridae to protect against brain infection. *Neuron.* 2018; 99(1): 56-63.e3.
416 DOI: 10.1016/j.neuron.2018.06.030.
- 417 11. **Poole S, Singhrao SK, Kesavalu L, Curtis MA, Crean S. Determining the presence
418 of periodontopathic virulence factors in short-term postmortem Alzheimer's disease
419 brain tissue. *J Alzheimers Dis.* 2013; 36(4): 665-77. DOI: 10.3233/JAD-121918. **The**
420 **original study confirmed that *P. gingivalis* lipopolysaccharide reaches the**
421 **Alzheimer disease brain.**
- 422 12. *Hajishengallis G, Darveau RP, Curtis MA. The keystone-pathogen hypothesis. *Nat*
423 *Rev Microbiol.* 2012; 10(10): 717-25. DOI: 10.1038/nrmicro2873. **The keystone-**
424 **pathogen hypothesis holds that certain low-abundance microbial pathogens can**
425 **orchestrate inflammatory disease by remodelling a normally benign microbiota**
426 **into a dysbiotic one.**
- 427 13. ***Poole S, Singhrao SK, Chukkapalli S, Rivera M, Velsko I, Kesavalu L, et al.
428 Active invasion of *Porphyromonas gingivalis* and infection-induced complement
429 activation in ApoE^{-/-} mice brains. *J Alzheimers Dis.* 2015; 43(1): 67-80. DOI:
430 10.3233/JAD-140315. ***P. gingivalis* was able to access the ApoE^{-/-} mice brain**
431 **contributing to complement activation by bystander neuronal injury.**
- 432 14. ***Ilievski V, Zuchowska PK, Green SJ, Toth PT, Ragazzino ME, Le K, et al.
433 Chronic oral application of a periodontal pathogen results in brain inflammation,
434 neurodegeneration and amyloid beta production in wild type mice. *PLoS One.* 2018;
435 13(10): e0204941. DOI: 10.1371/journal.pone.0204941. **First study to show**
436 **neurodegeneration and formation of extracellular A β 42 and phosphotau bound**
437 **to neurofibrillary tangles in young adult wild type mice after repeated**
438 **application of *P. gingivalis*.**

- 439 15. ***Wu Z, Ni J, Liu Y, Teeling JL, Takayama F, Collcutt A, et al. Cathepsin B plays a
440 critical role in inducing Alzheimer's disease-like phenotypes following chronic
441 systemic exposure to lipopolysaccharide from *Porphyromonas gingivalis* in mice.
442 Brain Behav Immun. 2017; 65: 350-61. DOI: 10.1016/j.bbi.2017.06.002. **Chronic**
443 **systemic exposure to PgLPS induced AD-like phenotypes, including microglia-**
444 **mediated neuroinflammation, intracellular A β accumulation in neurons and**
445 **impairment of the learning and memory functions in the middle-aged mice in a**
446 **CatB-dependent manner. Linked IL-1 β involvement in memory deterioration.**
- 447 16. **Ishida N, Ishihara Y, Ishida K, Tada H, Funaki-Kato Y, Hagiwara M, et al.
448 Periodontitis induced by bacterial infection exacerbates features of Alzheimer's
449 disease in transgenic mice. NPJ Aging Mech Dis. 2017; 3: 15. DOI: 10.1038/s41514-
450 017-0015-x. **Periodontitis caused by *P. gingivalis* may exacerbate brain A β**
451 **deposition, leading to increased cognitive impairments, by a mechanism that**
452 **involves triggering brain inflammation.**
- 453 17. **Ding Y, Ren J, Yu H, Yu W, Zhou Y. *Porphyromonas gingivalis*, a periodontitis
454 causing bacterium, induces memory impairment and age-dependent
455 neuroinflammation in mice. Immun Ageing. 2018; 15: 6. DOI: 10.1186/s12979-017-
456 0110-7. **The learning and memory abilities of the middle-aged mice infected with**
457 ***P. gingivalis* were impaired.**
- 458 18. Masters CL, Bateman R, Blennow K, Rowe CC, Sperling RA, Cummings JL.
459 Alzheimer's disease. Nat Rev Dis Primers. 2015; 1: 15056. DOI:
460 10.1038/nrdp.2015.56.
- 461 19. **Singhrao SK, Harding A, Chukkapalli S, Olsen I, Kesavalu L, Crean S.
462 Apolipoprotein E related co-morbidities and Alzheimer's disease. J Alzheimers Dis.
463 2016; 51(4): 935-48. DOI: 10.3233/JAD150690. **The apolipoprotein E gene allele 4**
464 **is the plausible commonality for the etiology of co-morbidities that eventually**
465 **result from periodontal diseases and ultimately progress to mixed pathologies**
466 **and dementia.**
- 467 20. Li J, Luo J, Liu L, Fu H, Tang L. The genetic association between apolipoprotein E
468 gene polymorphism and Parkinson disease: A meta-analysis of 47 studies. Medicine
469 (Baltimore). 2018; 97(43): e12884. DOI: 10.1097/MD.0000000000012884.
- 470 21. *Singhrao SK, Olsen I. Assessing the role of *Porphyromonas gingivalis* in
471 periodontitis to determine a causative relationship with Alzheimer's disease. J Oral
472 Microbiol. 2019; 1563405. DOI: 10.1080/20002297.2018.1563405. Summation of

- 473 animal studies supporting the *P. gingivalis* infection link with AD risk factor
474 development.
- 475 22. *Rokad F, Moseley R, Hardy RS, Chukkapalli S, Crean S, Kesavalu L, et al. Cerebral
476 oxidative stress and microvasculature defects in TNF- α expressing transgenic and
477 *Porphyromonas gingivalis*-infected ApoE^{-/-} mice. J Alzheimers Dis. 2017; 60(2): 359-
478 69. DOI: 10.3233/JAD-170304. **The hippocampal microvascular structure of *P.***
479 ***gingivalis*-infected ApoE^{-/-} mice possesses elevated oxidative stress levels,**
480 **resulting in the associated tight junction proteins being susceptible to increased**
481 **oxidative/proteolytic degradation, leading to hydrolysis of the amyloid precursor**
482 **protein to generate A β in wild type mice infected with *P. gingivalis*.**
- 483 23. ***Moir RD, Lathe R, Tanzi RE. The antimicrobial protection hypothesis of
484 Alzheimer's disease. Alzheimers Dement. 2018; 14(12): 1602-14. DOI:
485 10.1016/j.jalz.2018.06.3040. **The new Antimicrobial Protection Hypothesis reveals**
486 **brain microbial burden may directly generate β -amyloid deposits, inflammation,**
487 **and AD progression. This study underpins the role of microbes in the**
488 **pathogenesis of AD.**
- 489 24. ***Singhrao SK, Chukkapalli S, Poole S, Velsko I, Crean SJ, Kesavalu L. Chronic
490 *Porphyromonas gingivalis* infection accelerates the occurrence of age-related granules
491 in ApoE^{-/-} mice brains. J Oral Microbiol. 2017; 9(1):1270602. DOI:
492 10.1080/20002297.2016.1270602. **ApoE^{-/-} mice showing the earliest inflammation-**
493 **mediated tissue injury, accompanied by cerebral blood-brain barrier**
494 **breachment.**
- 495 25. **Bowman GL, Dayon L, Kirkland R, Wojcik J, Peyratout G, Severin IC, et al.
496 Blood-brain barrier breakdown, neuroinflammation, and cognitive decline in older
497 adults. Alzheimers Dement. 2018; 14(12):1640-50. DOI: 10.1016/j.jalz.2018.06.2857.
498 **Blood-brain-barrier breakdown is associated with cognitive decline and**
499 **inflammation in non-demented elders.**
- 500 26. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and
501 problems on the road to therapeutics. Science. 2002; 297(5580): 353-6. Erratum in:
502 Science 2002; 297(5590): 2209.
- 503 27. **Boche D, Donald J, Love S, Harris S, Neal JW, Holmes C, et al. Reduction of
504 aggregated Tau in neuronal processes but not in the cell bodies after Abeta42

- 505 immunisation in Alzheimer's disease. *Acta Neuropathol.* 2010; 120(1): 13-20.
- 506 **Removal of Aβeta from the brain via immunisation does not improve memory.**
- 507 28. *Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, et al. Physical
508 basis of cognitive alterations in Alzheimer's disease: synapse loss is the major
509 correlate of cognitive impairment. *Ann Neurol.* 1991; 30(4): 572-80. **Origins of the**
510 **synaptic loss theory to explain cognitive deficit.**
- 511 29. *Masliah E, Hansen L, Albright T, Mallory M, Terry RD. Immunoelectron
512 microscopic study of synaptic pathology in Alzheimer's disease. *Acta Neuropathol.*
513 1991; 81(4): 428-33. **Provides evidence to support the synaptic loss theory.**
- 514 30. **Cline EN, Bicca MA, Viola KL, Klein WL. The Amyloid-β Oligomer Hypothesis:
515 Beginning of the third decade. *J Alzheimers Dis.* 2018; 64(s1): S567-S610. DOI:
516 10.3233/JAD-179941. **Revised Amyloid-β oligomer theory. Soluble Aβ oligomers**
517 **accumulate in an AD-dependent manner in human and animal model brain**
518 **tissue and, experimentally, to impair learning and memory and instigate major**
519 **facets of AD neuropathology, including tau pathology, synapse deterioration and**
520 **loss, inflammation, and oxidative damage.**
- 521 31. **Olsen I, Singhrao SK. Inflammasome involvement in Alzheimer's disease. *J*
522 *Alzheimers Dis.* 2016; 5;54(1): 45-53. **This review supports the mechanism of *P.***
523 ***gingivalis* infection promoting cognitive deficit (see ref 52).**
- 524 32. Gatz M, Mortimer JA, Fratiglioni L, Johansson B, Berg S, Reynolds CA, et al.
525 Potentially modifiable risk factors for dementia in identical twins. *Alzheimers*
526 *Dement.* 2006; 2: 110-7.
- 527 33. Stein PS, Desrosiers M, Donegan SJ, Yepes JF, Kryscio RJ. Tooth loss, dementia and
528 neuropathology in the Nun study. *J Am Dent Assoc.* 2007; 138(10): 1314-22; quiz
529 1381-2.
- 530 34. Stein PS, Kryscio RJ, Desrosiers M, Donegan SJ, Gibbs MB. Tooth loss,
531 apolipoprotein E, and decline in delayed word recall. *J Dent Res.* 2010; 89(5): 473-7.
532 DOI: 10.1177/0022034509357881.
- 533 35. Kamer AR, Craig RG, Pirraglia E, Dasanayake AP, Norman RG, Boylan RJ, et al.
534 TNF-alpha and antibodies to periodontal bacteria discriminate between Alzheimer's
535 disease patients and normal subjects. *J Neuroimmunol.* 2009; 216(1-2): 92-7. DOI:
536 10.1016/j.jneuroim.2009.08.013.

- 537 36. *Farhad SZ, Amini S, Khalilian A, Barekataan M, Mafi M, Barekataan M, et al. The
538 effect of chronic periodontitis on serum levels of tumor necrosis factor-alpha in
539 Alzheimer disease. *Dent Res J (Isfahan)*. 2014; 11(5): 549-52. **Not all of the AD**
540 **cases they examined at the clinical level co-existed with periodontitis.**
- 541 37. **Sparks Stein P, Steffen MJ, Smith C, Jicha G, Ebersole JL, Abner E, et al. Serum
542 antibodies to periodontal pathogens are a risk factor for Alzheimer's disease.
543 *Alzheimers Dement*. 2012; 8(3): 196-203. DOI: 10.1016/j.jalz.2011.04.006. **A**
544 **laboratory study that agreed with the epidemiological study of Chen et al., (ref**
545 **38) for the 10 year timeline in risk development following periodontitis diagnosis**
- 546 38. **Chen CK, Wu YT, Chang YC. Association between chronic periodontitis and the
547 risk of Alzheimer's disease: a retrospective, population-based, matched-cohort study.
548 *Alzheimers Res Ther*. 2017; 9(1): 56. DOI: 10.1186/s13195-017-0282-6. **A 10-year**
549 **CP exposure was associated with a 1.707-fold increase in the risk of developing**
550 **AD.**
- 551 39. Stewart R, Weyant RJ, Garcia ME, Harris T, Launer LJ, Satterfield S, et al. Adverse
552 oral health and cognitive decline: the health, aging and body composition study. *J Am*
553 *Geriatr Soc*. 2013; 61(2): 177-84. DOI: 10.1111/jgs.12094.
- 554 40. Kaye EK, Valencia A, Baba N, Spiro A, 3rd, Dietrich T, Garcia RI. Tooth loss and
555 periodontal disease predict poor cognitive function in older men. DOI:
556 10.1111/j.1532-5415.2010.02788.x.
- 557 41. *Daly B, Thompsell A, Sharpling J, Rooney YM, Hillman L, Wanyonyi KL, et al.
558 Evidence summary: the relationship between oral health and dementia. *Br Dent J*.
559 2018;223(11): 846-53. DOI: 10.1038/sj.bdj.2017.992. **Poor oral hygiene is**
560 **associated with dementia, and more so amongst people in advanced stages of the**
561 **disease.**
- 562 42. *de Souza Rolim T, Fabri GM, Nitrini R, Anghinah R, Teixeira MJ, de Siqueira JT, et
563 al. Oral infections and orofacial pain in Alzheimer's disease: a case-control study. *J*
564 *Alzheimers Dis*. 2014; 38(4): 823-9. DOI: 10.3233/JAD-131283. **An interventional**
565 **study on the periodontal treatment in AD patients indicated a plausible causal**
566 **relationship in demented individuals.**
- 567 43. *Emanuel R, Sorensen A. A study of oral health prevention behaviours for patients
568 with early stage dementia. *Br Dent J*. 2018; 224(1): 38-42. DOI:
569 10.1038/sj.bdj.2018.5. **There was clearly scope for improving oral health**
570 **education and prevention for dementia patients.**

- 571 44. *Hajishengallis G. Immune evasion strategies of *Porphyromonas gingivalis*. J Oral
572 Biosci. 2011; 53(3): 233-40. **Exploitation of Toll-like receptor-2, complement**
573 **receptor 3, C5a anaphylatoxin receptor, and CXC-chemokine receptor 4 by *P.***
574 ***gingivalis* allows the pathogen to escape elimination, obtain nutrients, and**
575 **collaterally inflict periodontal tissue injury.**
- 576 45. *Hajishengallis G, Lambris JD. Complement and dysbiosis in periodontal disease.
577 Immunobiology. 2012; 217(11): 1111-6. DOI: 10.1016/j.imbio.2012.07.007. *P.*
578 *gingivalis* expresses C5 convertase-like enzymatic activity and adeptly exploits
579 complement-TLR crosstalk to subvert host defenses and escape elimination.
- 580 46. Hajishengallis G, Abe T, Maekawa T, Hajishengallis E, Lambris JD. Role of
581 complement in host-microbe homeostasis of the periodontium. Semin Immunol. 2013;
582 25(1): 65-72. DOI: 10.1016/j.smim.2013.04.004.
- 583 47. Hussain M, Stover CM, Dupont A. *P. gingivalis* in periodontal disease and
584 atherosclerosis - scenes of action for antimicrobial peptides and complement. Front
585 Immunol. 2015; 6: 45. DOI: 10.3389/fimmu.2015.00045.
- 586 48. Olsen I, Hajishengallis G. Major neutrophil functions subverted by *Porphyromonas*
587 *gingivalis*. J Oral Microbiol. 2016; 8: 30936. DOI: 10.3402/jom.v8.30936.
- 588 49. Olsen I, Singhrao SK, Osmundsen H. Periodontitis, pathogenesis and progression:
589 miRNA-mediated cellular responses to *Porphyromonas gingivalis*. J Oral Microbiol.
590 2017; 9(1): 1333396. DOI: 10.1080/20002297.2017.1333396.
- 591 50. ***Dominy SS, Lynch C, Ermini F, Benedyk M, Marczyk A, Konradi A, et al.
592 *Porphyromonas gingivalis* in Alzheimer's disease brains: Evidence for disease
593 causation and treatment with small-molecule inhibitors. *Sci. Adv.* 2019; 5: eaau3333.
594 **This study has provided the strongest evidence for causal links of *P. gingivalis***
595 **infection with AD. It has raised the vital awareness in periodontitis and AD**
596 **developmental links. It offers hope for a future treatment via their gingipain**
597 **inhibiting drugs**
- 598 51. **Llorente P, Kristen H, Sastre I, Toledano-Zaragoza A, Aldudo J, Recuero M, et al. A
599 free radical-generating system regulates amyloid oligomers: Involvement of cathepsin
600 B. J Alzheimer's Dis. 2018; 66: 1397-408. DOI 10.3233/JAD-170159. **Cathepsin B**
601 **participates in the changes of amyloid oligomer induced by mild oxidative stress.**
602 **This supports the oxidative stress related damage following *P. gingivalis* infection**
603 **as reported in reference 22.**

- 604 52. **Zhang J, Yu C, Zhang X, Chen H, Dong J, Lu W, et al. *Porphyromonas gingivalis*
605 lipopolysaccharide induces cognitive dysfunction, mediated by neuronal inflammation
606 via activation of the TLR4 signaling pathway in C57BL/6 mice. *J Neuroinflammation*.
607 2018; 15(1): 37. DOI: 10.1186/s12974-017-1052-x. **Offer a mechanism of how *P.***
608 ***gingivalis*-LPS-induced neuroinflammation plays an important role in cognitive**
609 **impairment. This reference complements the review by Olsen and Singhrao**
610 **reference no 31.**
- 611 53. Imamura T. The role of gingipains in the pathogenesis of periodontal disease. *J*
612 *Periodontol*. 2003; 74(1): 111-8.
- 613 54. *Carter CJ, France J, Crean S, et al. The *Porphyromonas gingivalis*/host interactome
614 shows enrichment in GWASdb genes related to Alzheimer's disease, diabetes and
615 cardiovascular diseases. *Front Aging Neurosci*. 2017; 9: 408. DOI:
616 10.3389/fnagi.2017.00408 ***P. gingivalis* interactome supporting AD susceptibility**
617 **genes or gene expression changes. In particular lists the supporting references for**
618 **eroding proteins that keep epithelial/endothelial barriers intact.**
- 619 55. Cunningham C, Wilcockson DC, Campion S, Lunnon K, Perry VH. Central and systemic
620 endotoxin challenges exacerbate the local inflammatory response and increase neuronal
621 death during chronic neurodegeneration. *J Neurosci*. 2005; 25: 9275-84.
- 622 56. Tanaka S, Ide M, Shibutani T, Ohtaki H, Numazawa S, Shioda S, et al.
623 Lipopolysaccharide-induced microglial activation induces learning and memory deficits
624 without neuronal cell death in rats. *J Neurosci Res*. 2006; 83: 557-66.
- 625 57. Chen J, Buchanan JB, Sparkman NL, Godbout JP, Freund GG, Johnson RW.
626 Neuroinflammation and disruption in working memory in aged mice after acute
627 stimulation of the peripheral innate immune system. *Brain Behav Immun*. 2008; 18:
628 223-30.
- 629 58. *Henry CJ, Huang Y, Wynne AM, Godbout JP. Peripheral lipopolysaccharide (LPS)
630 challenge promotes microglial hyperactivity in aged mice that is associated with
631 exaggerated induction of both pro-inflammatory IL-1beta and anti-inflammatory IL-10
632 cytokines. *Brain Behav Immun*. 2009; 23(3): 309-17. Implicates LPS with release of IL-
633 1β and intracerebral inflammation
- 634 59. *Bellinger FP, Madamba S, Siggins, GR. Interleukin 1 beta inhibits synaptic strength
635 and long-term potentiation in the rat CA1 hippocampus. *Brain Res*. 1993; 628: 227-34.
636 Implicate IL-1β in cognitive deficit.

- 637 60. Mishra A, Kim HJ, Shin AH, Thayer SA. Synapse loss induced by interleukin-1beta
638 requires pre- and post-synaptic mechanisms. *J Neuroimmune Pharmacol.* 2012; 7(3):
639 571-8. DOI: 10.1007/s11481-012-9342-7.
- 640 61. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, et al. Inflammation and
641 Alzheimer's disease. *Neurobiol Aging.* 2000; 21(3): 383-421.
- 642 62. Allen HB. Alzheimer's disease: Assessing the role of spirochetes, biofilms, the immune
643 system, and amyloid- β with regard to potential treatment and prevention. *J Alzheimers*
644 *Dis.* 2016; 53(4):1271-6. DOI: 10.3233/JAD-160388.
- 645 63. Singhrao SK, Neal JW, Rushmere NK, Morgan BP, Gasque P. Spontaneous classical
646 pathway activation and deficiency of membrane regulators render human neurons
647 susceptible to complement lysis. *Am J Pathol.* 2000; 157(3): 905-18.
- 648 64. Wingrove JA, DiScipio RG, Chen Z, Potempa J, Travis J, Hugli TE. Activation of
649 complement components C3 and C5 by a cysteine proteinase (gingipain-1) from
650 *Porphyromonas (Bacteroides) gingivalis*. *J Biol Chem.* 1992; 267(26): 18902-7.
- 651 65. Popadiak K, Potempa J, Riesbeck K, Blom AM. Biphasic effect of gingipains from
652 *Porphyromonas gingivalis* on the human complement system. *J Immunol.* 2007;
653 178(11): 7242-50.
- 654 66. Potempa M, Potempa J, Okroj M, Popadiak K, Eick S, Nguyen KA, et al. Binding of
655 complement inhibitor C4b-binding protein contributes to serum resistance of
656 *Porphyromonas gingivalis*. *J Immunol.* 2008; 181(8): 5537-44.
- 657 67. Slaney JM, Curtis MA. Mechanisms of evasion of complement by *Porphyromonas*
658 *gingivalis*. *Front Biosci.* 2008; 13: 188-96.
- 659 68. Wang M, Krauss JL, Domon H, Hosur KB, Liang S, Magotti P, et al. Microbial
660 hijacking of complement-toll-like receptor crosstalk. *Sci Signal.* 2010; 3(109): ra11.
661 DOI: 10.1126/scisignal.2000697.
- 662 69. *Olsen I, Singhrao SK. Genetic defects, complement and *Porphyromonas gingivalis*
663 immune subversion in Alzheimer's disease. *J Oral Microbiol.* 2018; submitted. **P.**
664 ***gingivalis* is a keystone pathogen for periodontitis and its co-morbidities because**
665 **of the mastery of this bacterium at subverting selective steps in the immune**
666 **system for effective dysbiosis, which in turn amplifies altered gene functions in**
667 **Alzheimer's disease.**
- 668 70. *Bielecka E, Scavenius C, Kantyka T, Jusko M, Mizgalska D, Szmigielski B, et al.
669 Peptidyl arginine deiminase from *Porphyromonas gingivalis* abolishes anaphylatoxin
670 C5a activity. *J Biol Chem.* 2014; 289(47): 32481-7. DOI: 10.1074/jbc.C114.617142. **In**

- 671 **the context of previous studies, which showed crosstalk between C5aR and Toll-**
672 **like receptors, and enhanced arthritis development in mice infected with PPAD-**
673 **expressing *P. gingivalis*, a crucial role of PPAD in the virulence of *P. gingivalis***
674 **was supported.**
- 675 71. *Liu Y, Wu Z, Nakanishi Y, Ni J, Hayashi Y, Takayama F, et al. Infection of microglia
676 with *Porphyromonas gingivalis* promotes cell migration and an inflammatory response
677 through the gingipain-mediated activation of protease-activated receptor-2 in mice. *Sci*
678 *Rep.* 2017; 7(1): 11759. DOI: 10.1038/s41598-017-12173-1. **The authors provide the**
679 **first evidence that Rgp and Kgp cooperatively contribute to the *P. gingivalis*-**
680 **induced cell migration and expression of proinflammatory mediators through the**
681 **activation of protease-activated receptor 2.**
- 682 72. Choi JW, Kim SC, Hong SH, Lee HJ. Secretable small RNAs via outer membrane
683 vesicles in periodontal pathogens. *J Dent Res.* 2017; 96: 458–66. DOI:
684 10.1177/0022034516685071.
- 685 73. *Singh Rao SK, Olsen I. Are *Porphyromonas gingivalis* outer membrane vesicles,
686 microbullets for sporadic Alzheimer's disease manifestation? *J Alzheimers Dis Rep.*
687 2018; 1: 1-10. DOI: 10.3233/ADR-180080. **Bacterial cultures and established oral**
688 **biofilms generate vast numbers of microvesicles and *P. gingivalis* outer membrane**
689 **vesicles encase key virulence factors (LPS, gingipains, capsule, fimbriae) as**
690 **though they are complete destructive "microbullets" when shed in the host.**
- 691 74. Schertzer JW, Whiteley M. Microbial communication superhighways. *Cell.* 2011;
692 144(4): 469-70. DOI: 10.1016/j.cell.2011.02.001.
- 693 75. **Adamowicz K, Wang H, Jotwani R, Zeller I, Potempa J, Scott DA. Inhibition of
694 GSK3 abolishes bacterial-induced periodontal bone loss in mice. *Mol Med.* 2012; 18:
695 1190-6. DOI: 10.2119/molmed.2012.00180. **This study confirms the relevance of**
696 **prior *in vitro* phenomena and establish GSK3 as a novel, efficacious therapeutic**
697 **preventing periodontal disease progression in a susceptible host.**
- 698 76. Wang H, Brown J, Martin M. Glycogen synthase kinase 3: a point of convergence for
699 the host inflammatory response. *Cytokine.* 2011;53: 130–40.
- 700 77. Baek H, Ye M, Kang GH, Lee C, Lee G, Choi DB, et al. Neuroprotective effects of
701 CD4⁺CD25⁺Foxp3⁺ regulatory T cells in a 3xTg-AD Alzheimer's disease model.
702 *Oncotarget.* 2016; 7(43): 69347-57. DOI: 10.18632/oncotarget.12469.


- 703 78. Yang J, Wu J, Liu Y, Huang J, Lu Z, Xie L, et al. *Porphyromonas gingivalis* infection
 704 reduces regulatory T cells in infected atherosclerosis patients. PLoS One. 2014; 9(1):
 705 e86599. DOI: 10.1371/journal.pone.0086599.
- 706 79. Gonçalves LS, Ferreira SM, Silva A Jr, Villoria GE, Costinha LH, Souto R, et al.
 707 Association of T CD4 lymphocyte levels and subgingival microbiota of chronic
 708 periodontitis in HIV-infected Brazilians under HAART. Oral Surg Oral Med Oral
 709 Pathol Oral Radiol Endod. 2004; 97(2): 196-203.
- 710 80. Emery DC, Shoemark DK, Batstone TE, Waterfall CM, Coghill JA, Cerajewska TL, et
 711 al. 16S rRNA Next Generation Sequencing analysis shows bacteria in Alzheimer's
 712 post-mortem brain. Front Aging Neurosci. 2017; 9: 195. DOI:
 713 10.3389/fnagi.2017.0019.

714 715 716 **Figure legends**

717 **Figure 1.** Western blot showing CD14 protein on the human neuroblastoma cell line
 718 IMR32. **a)** is an immunoblot of cell lysate prepared from IMR32 neurons following
 719 ~~their standard growth culture medium and incubation conditions, no exposure to~~
 720 ~~virulence factors (control) (lane 1), and eIMR32 neurons cultured in their growth~~
 721 ~~medium to which control with *P. gingivalis* sterile growth medium diluted 1:4 from~~
 722 ~~stock for *P. gingivalis* was added cultures (lane 2), IMR32 neurons in their growth~~
 723 ~~medium plus *P. gingivalis* ATCC 33277^T conditioned medium diluted 1:4 from stock~~
 724 ~~(lane 3) with exposure (test) to *P. gingivalis* ATCC 33277^T (lane 3) and strain W50~~
 725 ~~conditioned medium (diluted 1:4 from stock) (lane 4) spent medium (diluted 1:4 from~~
 726 ~~stock) for 24 h. The proteins were separated by SDS-PAGE electrophoresis and~~
 727 electro transferred onto the PVDF (polyvinylidene difluoride) membrane. Following
 728 incubation of the membrane overnight with mouse anti-CD14 antibody, clear bands
 729 around the 55 kDa molecular weight were seen (in the control lanes 1 and 2, long
 730 arrow) indicating ~~that the CD14 receptor protein was expressed present on control~~
 731 ~~by these~~ cells. Upon challenge with *P. gingivalis* 33277^T the band completely
 732 diminished (lane 3, CD14 cleaved from cell membrane). Treatment of the same cells
 733 with the W50 strain surprisingly, only partially cleaved CD14 (lane 4) as compared
 734 with the control lanes 1 and 2. **b)** IMR32 cells grown on coverslips were also
 735 incubated with the same anti-CD14 antibody. The green colour shows CD14 labelling
 736 on the surface membrane of cells ~~confirming meaning~~ that the receptor is intact. The

737 red colour indicates the nucleus due to propidium iodide uptake from the mounting
 738 medium. **c)** Following exposure to *P. gingivalis* 33277^T, the cells for 24 h (as for the
 739 blot), the green labelling was missing and correlated with the blot data. **d)** Exposure to
 740 *P. gingivalis* W50, demonstrated green labelling on the membranes again correlating
 741 with the blot data.
 742
 743

Figure 1.



744

745


746

Figure 2

747 IMR32 neurons in culture: Fluorescein-phalloidin (5 units/ml final, for 30 min)
 748 labelling for actin cytoskeletal protein (green), (nuclei = red due to propidium
 749 iodide uptake). **a)** IMR32 monolayer in growth medium shows long processes of
 750 the cells extending outwards. **b)** Exposure to *P. gingivalis* ATCC 33277^T, spent
 751 medium (diluted 1:4) for 6 h demonstrated the processes thickened, whilst the cell
 752 soma enlarged. **c)** As for b, but after 24 h exposure, the cells rounded up and
 753 detached. Images taken after examining the cells under the 510 series Zeiss

754 confocal microscope (Carl Zeiss Ltd). Micron bar = 10

Figure 2.



755